Geron Corp (GERN)

[subslover]

Geron surges after publication of IMbark Phase 2 data
Jun. 17, 2021 11:22 PM ETGeron Corporation (GERN)By: Carl Surran, SA News Editor3 Comments
Geron (NASDAQ:GERN) +19.8% post-market after reporting the publication of data supporting the ongoing IMbark Phase 2 clinical trial in the Journal of Clinical Oncology.
Geron says the publication "highlights the clinical benefits observed in the study, including symptom response and overall survival, as well as the evidence of disease-modifying activity from biomarker and bone marrow fibrosis assessments."
The company is evaluating imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis, a rare type of blood cancer.
Geron says data from the Phase 2 clinical trials offers "strong evidence that imetelstat targets telomerase to inhibit the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies resulting in malignant cell apoptosis and potential disease-modifying activity."